ALVO

ALVO

USD

Alvotech Ordinary Shares

$4.830-0.260 (-5.108%)

Reaalajas hind

Healthcare
Drug Manufacturers - Specialty & Generic
Luksemburg

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$5.090

Kõrge

$5.100

Madal

$4.700

Maht

0.89M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

1.5B

Tööstusharu

Drug Manufacturers - Specialty & Generic

Riik

Luxembourg

Kauplemisstatistika

Keskmine maht

0.47M

Börs

NGM

Valuuta

USD

52 nädala vahemik

Madal $4.7Praegune $4.830Kõrge $13.7

Seotud uudised

GlobeNewswire

Alvotech INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (ALVO)

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Alvotech ("Alvotech" or the "Company") (NASDAQ:ALVO). The investigation concerns whether the

Vaata rohkem
Alvotech INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (ALVO)
Analyst Upgrades

Deutsche Bank Downgrades Alvotech to Hold, Lowers Price Target to $8

Deutsche Bank analyst Niall Alexander downgrades Alvotech from Buy to Hold and lowers the price target from $14 to $8.

Vaata rohkem
Deutsche Bank Downgrades Alvotech to Hold, Lowers Price Target to $8
GlobeNewswire

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today

Vaata rohkem
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
GlobeNewswire

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

REYKJAVIK, Iceland, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced

Vaata rohkem
Alvotech Announces Changes in Global Business Development and Commercial Operations Team